When was Concert AI founded?

Concert AI was founded in 2018 and became a unicorn in 2022, reaching the milestone in 4 years. It raised its 1st funding round 2 years after its incorporation.

Where is Concert AI located?

Concert AI is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

How many employees does Concert AI have?

As of Apr 30, 2026, the latest employee count at Concert AI is 828.

Is Concert AI a funded company?

Concert AI is a funded company, having raised a total of $300M across 2 funding rounds to date. The company's 1st funding round was a $150M Series B round, raised on Jan 13, 2020.

How much is Concert AI worth?

The latest valuation of Concert AI is $1.9B as of Mar 29, 2022.

When was the latest funding round of Concert AI?

Concert AI's latest funding was a $150M Series C round on Mar 29, 2022, with participation from 1 investor.

Is Concert AI a Data as a Service company?

The primary sectors of Concert AI are Data as a Service and Life Sciences Tech.

Where does Concert AI rank among its competitors?

Concert AI ranks 3rd amongst 198 active competitors, of which 20 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Owkin, which secured $33M in Mar, 2026.

Who are the top competitors of Concert AI?

Concert AI's top competitors include Owkin, Novotech and Bioptimus. Among them, Owkin secured the most recent funding round in March, 2026.

Concert AI - 2026 Company Profile, Team, Funding & Competitors

Concert AI is a series C company based in Boston (United States), founded in 2018 by Romesh Wadhwani. It operates as a Provider of AI and real-world data solutions for life sciences. Concert AI has raised $300M in funding from Sixth Street and Declaration Partners, with a current valuation of $1.9B. The company has 198 active competitors, including 20 funded and 31 that have exited. Its top competitors include companies like Owkin, Novotech and Bioptimus.

Sectors and market segments that Concert AI operate in

Concert AI serves in the HealthTech, Life Sciences market segments.The primary business model of Concert AI are:

Company Details

Provider of AI and real-world data solutions for life sciences. The company delivers regulatory and research solutions, precision suites, and commercial solutions. It also offers clinical development tools and cancer care solutions. The company's offerings include advanced visualization and AI-driven automation for medical imaging.

Website: www.concertai.com/
Social
Email ID: *****@concertai.com
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

2018

Location

Boston, United States

Stage

Series C

Total Funding

$300M in 2 rounds

Latest Funding Round

Series C, Mar 29, 2022, $150M

Post Money Valuation

$1.9B as on Mar 29, 2022

Investors

Sixth Street & 4 more

Ranked

3^rd among 198 active competitors

Employee Count

828 as on Apr 30, 2026

Investment & Acquisitions

CancerLinQ

Similar Companies

Owkin & 203 more

View Concert AI's full profile

Concert AI is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CONCERTAI LLC CIN: 32090029342 , United States, Active		-	-	-
CONCERTO HEALTHAI SOLUTIONS CIN: 822784254 , United States, Active	Dec 31, 1999	-	410 (As on Dec 31, 2024)	-

Concert AI has raised a total funding of $300M over 2 rounds. Its first funding round was on Jan 13, 2020. Its latest funding round was a Series C round on Mar 29, 2022 for $150M. 1 investor participated in its latest round. Concert AI has 5 institutional investors.

Here is the list of recent funding rounds of Concert AI:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 29, 2022	$150M	Series C	$1.9B	-	Sixth Street	-
Jan 13, 2020	$150M	Series B	-	-	Declaration Partners	Maverick Ventures, AllianceBernstein, SymphonyAI

Access funding benchmarks and valuations. Sign up today!

View details of Concert AI's funding rounds and investors

The founders of Concert AI is Romesh Wadhwani.

Here are the details of Concert AI's key team members:

Romesh Wadhwani: Former Founder of Concert AI and founder of 5 other companies, including Wadhwani Foundation, Wadhwani AI and STG Partners.

View details of Concert AI's Founder profiles and Board Members

Concert AI's employee count trend

Concert AI has 828 employees as of Apr 26. Here is Concert AI's employee count trend over the years:

Uncover Concert AI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Concert AI include Owkin, Novotech and Bioptimus. Here is the list of Top 10 competitors of Concert AI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Owkin 2016, Paris (France), Series B	Developer of agentic AI platform for biomedical research and drug development	$354M	AIC, Google Ventures & 20 others	71/100
2nd	Novotech 2002, Sydney (Australia), Acquired	Provider of clinical research services across all trial phases and therapeutic areas	$255M	GIC, Temasek & 4 others	68/100
3rd	Concert AI 2018, Boston (United States), Series C	Provider of AI and real-world data solutions for life sciences	$300M	Sixth Street, Maverick Ventures & 3 others	64/100
4th	Bioptimus 2024, Paris (France), Series A	Developer of AI foundation model to transform biological research	$76M	Cathay Innovation, Bpifrance & 15 others	62/100
5th	Dotmatics 2005, Bishop s Stortford (United Kingdom), Acquired	AI powered scientific data management and workflow automation solutions	$11.3M	Scottish Equity Partners, Insight Partners ... & 4 others	62/100
6th	H1 2017, New York City (United States), Series C	Provider of medical affair services for biopharma and medical device industry	$321M	IVP, Altimeter Capital & 13 others	59/100
7th	Digital Science 2010, London (United Kingdom), Funding Raised	Research assistance software solutions	-	HHS	56/100
8th	Sygnature Discovery 2004, Nottingham (United Kingdom), Series A	Provider of services and products for integrated drug discovery	-	Rothschild & Co, Five Arrows Principal Investments ... & 4 others	56/100
9th	Doctor Evidence 2004, Santa Monica (United States), Acquired	Evidence based medical decision solutions for multiple healthcare stakeholders	$1.5M	Wormhole Capital, Costella Kirsch	56/100
10th	Instem 1969, Conshohocken (United States), Acquired	Software solutions for data collection, management, and analysis for the life science industry	-	Eiffel Investment Group, Europa & 1 others	56/100